Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Conditions

Recurrence 2Ovarian Neoplasms 2Myelodysplastic Syndromes 2Leukemia, Myeloid, Acute 2Urinary Bladder Neoplasms 1Stomach Neoplasms 1Prostatic Neoplasms 1Myeloproliferative Disorders 1Myeloid Malignancy 1MDS 1Leukemia, Myelomonocytic, Chronic 1Hematologic Neoplasms 1Carcinoma, Transitional Cell 1Carcinoma, Non-Small-Cell Lung 1

Interventions

venetoclax 1eprenetapopt 1Azacitidine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Myeloid Malignancy × eprenetapopt × Clear all
NCT04214860 2025-03-17

APR-246 in Combination With Venetoclax and Azacitidine in TP53-Mutant Myeloid Malignancies

Aprea Therapeutics

Phase 1 Completed
51 enrolled 9 charts

Myeloid Malignancy

Data powered by HemOnc (CC BY 4.0) Colophon âš¡